Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K, check for updates.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on November 26, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates a regulatory update from Axsome Therapeutics, Inc., which may contain important information for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosed material events or financial impacts.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- November 26, 2024 (date) — Date of earliest event reported
- 001-37635 (other) — Commission File Number
- 45-4241907 (other) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for Axsome Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 26, 2024.
What is the Commission File Number for Axsome Therapeutics, Inc.?
The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.
What is the IRS Employer Identification Number for Axsome Therapeutics, Inc.?
The IRS Employer Identification Number for Axsome Therapeutics, Inc. is 45-4241907.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 26, 2024.
What is the principal executive office address for Axsome Therapeutics, Inc.?
The principal executive office address for Axsome Therapeutics, Inc. is One World Trade Center, 22nd Floor, New York, New York, 10007.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-11-26 07:05:36
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20241126.htm (8-K) — 41KB
- axsm-ex99_1.htm (EX-99.1) — 60KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-130755.txt ( ) — 251KB
- axsm-20241126.xsd (EX-101.SCH) — 23KB
- axsm-20241126_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 26, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing the results of its ENCORE (Evaluating Continued Treatment with Reboxetine) Phase 3 trial of the Company's AXS-12 product candidate for the treatment of narcolepsy. The full text of the press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: November 26, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer